# Effectiveness of a Repetitive Use of 24-hour Levosimendan Infusions in Patients With Severe Systolic Heart Failure in Order to Prevent Rehospitalizations

Study · id `cardio:ct-nct03764722` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03764722](<https://clinicaltrials.gov/study/NCT03764722>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03764722

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

## Technical summary

Registry record NCT03764722. Allocation not applicable; no masking; primary purpose treatment. Start 2018-08-01 (actual); primary completion 2021-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT03764722, source copy `cardio:ctgov-nct03764722-2018-12-05`, retrieved 2026-10-26)
- Started: 2018-08-01 (actual) (ClinicalTrials.gov record NCT03764722, source copy `cardio:ctgov-nct03764722-2018-12-05`, retrieved 2026-10-26)
- Primary completion: 2021-12-31 (anticipated) (ClinicalTrials.gov record NCT03764722, source copy `cardio:ctgov-nct03764722-2018-12-05`, retrieved 2026-10-26)
- Completion: 2021-12-31 (anticipated) (ClinicalTrials.gov record NCT03764722, source copy `cardio:ctgov-nct03764722-2018-12-05`, retrieved 2026-10-26)
- Countries: Poland (ClinicalTrials.gov record NCT03764722, source copy `cardio:ctgov-nct03764722-2018-12-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03764722-2018-12-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effectiveness of a Repetitive Use of 24-hour Levosimendan Infusions in Patients With Severe Systolic Heart Failure in Order to Prevent Rehospitalizations
- Condition: Systolic Heart Failure
- Intervention (Drug): Levosimendan
- Lead sponsor: Collegium Medicum w Bydgoszczy
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Heart failure with reduced ejection fraction (HFrEF) (`cardio:hfref`)
- Registry lists this organization as the lead sponsor: Collegium Medicum w Bydgoszczy (`cardio:org-collegium-medicum-w-bydgoszczy`)

## Provenance

Content hash: 3e74a41b080b7835413b6fd99bb2a8c18e85821b42b22f67e66d2ff3ae8e5adf
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
